STOCK TITAN

Skye Bioscience, Inc. - $skyed STOCK NEWS

Welcome to our dedicated page for Skye Bioscience news (Ticker: $skyed), a resource for investors and traders seeking the latest updates and insights on Skye Bioscience stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Skye Bioscience's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Skye Bioscience's position in the market.

Rhea-AI Summary
Skye Bioscience to host virtual Investor Day and release Phase 1 clinical data
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.21%
Tags
conferences
-
Rhea-AI Summary
Skye Bioscience announces patient enrollment starting in Q4 2023 for proof-of-concept P2a study of CB1 agonist. DEA authorizes three clinical trial sites for Phase 2a study of SBI-100 OE. Safety data for Phase 1 study to be reported in October. Financing fully funded Phase 2a study. Positive outcome critical for development of SBI-100 OE. Interim analysis expected in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.76%
Tags
-
Rhea-AI Summary
Skye Bioscience, Inc. (OTCQB: SKYED) will be presenting a corporate overview at the 2023 Cantor Global Healthcare Conference and the 16th Annual LD Micro Main Event. Punit Dhillon, Chairman and CEO, will be available for 1:1 meetings with investors during the conference. Interested parties can register to watch the presentation virtually. Tu Diep, Chief Development Officer, will also be presenting at the LD Micro Main Event and will be available for 1:1 meetings with investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.95%
Tags
conferences
Skye Bioscience, Inc.

OTC:SKYED

SKYED Rankings

SKYED Stock Data

10.88M
1.11M
General Freight Trucking, Long-Distance, Truckload
Transportation and Warehousing
Link
US
San Diego

About SKYED

nemus bioscience is a publicly traded, life-science biotech company, developing regulatory-approved, cannabinoid-based therapies, for a spectrum of diseases, especially those of unmet medical need.